GLOW Peptide Blend: GHK-Cu, TB-500 and BPC-157

Key facts

Components: GHK-Cu, TB-500, BPC-157. Amounts per vial are listed on the batch COA.

01 What is the GLOW peptide blend?

The GLOW peptide blend (people also search for it as the glow blend peptide) is one research product holding three separate compounds. They are the copper peptide GHK-Cu, TB-500, a peptide related to thymosin beta-4, and BPC-157, a pentadecapeptide. The name comes from the research-peptide market. It implies nothing about appearance, skin or any other effect.

Nothing bonds the three together. Their sizes are very different, too (see what is molecular weight): GHK-Cu is a copper-bound tripeptide of about 403 g/mol, while TB-500 can approach 5,000 g/mol depending on which form is used. That spread is exactly why a multi-component product needs documentation at the component level.

02 GLOW blend composition and quantity of each compound

The GLOW peptide blend (BBG70) holds 70 mg in total, split across three components. How much of each is present will appear on the batch record and the certificate of analysis for every batch. The total can't tell you the ratio between the peptides, so treat the per-compound figures on the COA as the reference.

03 What is GHK-Cu?

GHK-Cu is the copper(II) complex of GHK, the tripeptide glycine-histidine-lysine (GHK). PubChem lists the complex as C₁₄H₂₃CuN₆O₄⁺ (CID 71587328) at 402.9 g/mol, and the CAS number is 89030-95-5. GHK was first reported in human serum in 1973 ^[1]. Later, X-ray crystallography and solution studies worked out how copper binds to it ^[2]. Because GHK and GHK-Cu have different formulas, they are different substances, and the product record should say which form is supplied. The GHK-Cu compound page has more.

04 What is TB-500?

TB-500 is a trade name for a synthetic peptide related to thymosin beta-4. That parent molecule is a 43-amino-acid protein, first fully sequenced from bovine thymus in 1981 ^[3], with the formula C₂₁₂H₃₅₀N₅₆O₇₈S and a weight of about 4963 g/mol (PubChem CID 45382195). The trouble is that the name gets used loosely. Some materials sold as TB-500 match the full sequence; others are a short fragment, and work on short active-site sequences of thymosin beta-4 treats those fragments as distinct molecules ^[4]. So the product record states the exact TB-500 sequence in each Vinnix batch. Details are on the TB-500 compound page.

05 What is BPC-157?

The third component, BPC-157, is a synthetic 15-amino-acid peptide (a pentadecapeptide). Its sequence is GEPPPGKPADDAGLV, read from the N-terminal glycine to the C-terminal valine. PubChem files it under CID 9941957 with the molecular formula C₆₂H₉₈N₁₆O₂₂ and a molecular weight of 1419.5 g/mol; the CAS number is 137525-51-0. Salt forms such as the acetate have a different formula and weight, so a product record should name the form present. Identity data, terminology and literature are collected on the BPC-157 compound page.

Most of what has been published on BPC-157 is laboratory and animal work, such as cell-culture studies of tendon fibroblasts ^[5]. A 2025 systematic review called the evidence base predominantly preclinical ^[6].

06 Why do these compounds appear together in research?

Why these three? Each has its own independent body of laboratory and animal literature. They have not been studied together as a single product, and we know of no peer-reviewed controlled study of this exact three-way combination.

Every study above looked at one compound, so none of them describes GLOW. And because the work is preclinical (in vitro vs. in vivo research explains the categories), it should not be read as establishing safety or effectiveness in humans.

07 How is a three-component glow peptide blend analyzed?

Testing a blend means analyzing it one component at a time. Each peptide needs its own identity result and its own quantity result (identity vs. purity explains why those are separate questions); a single purity figure for the whole vial doesn't cut it. That's the main practical difference from testing a single compound, and peptide testing and analysis goes into it further.

1. Separation. HPLC separates the sample so that GHK-Cu, TB-500 and BPC-157 appear as distinct peaks at different retention times.
2. Identity. Mass spectrometry measures the molecular mass behind each peak and checks it against the expected value for that component. LC-MS performs both steps in one run.
3. Quantity. Each peak is compared with a reference standard for that specific peptide, which gives an amount per component rather than a single total.
4. Purity. Related impurities are assessed for each component, because a high overall area percentage can hide a problem with one peptide.

GHK-Cu needs a step the other two don't. As a metal complex, its copper content can be confirmed by elemental analysis when the testing program includes that test, and its mass spectrum may show free GHK peptide next to the copper-bound form. For TB-500, the result should match the sequence on the product record, full length or fragment.

08 GLOW vs Wolverine vs KLOW

In the Vinnix catalog, the GLOW peptide blend falls between the two-component Wolverine blend and the KLOW research blend.

09 GLOW blend COA and batch documentation

Each GLOW peptide blend batch (BBG70) will be documented with a certificate of analysis, and you should match it to the batch number on your vial. A good blend COA reports every component separately. The Vinnix COA Library will list reports by product, SKU and batch as they're published, and each is expected to show:

• Product name, SKU and batch or lot number that match the vial label
• Identity result for each component, usually by mass spectrometry
• Quantity of each component, so the per-compound amounts can be checked
• HPLC chromatogram with each peak labelled
• Testing laboratory, test date and the methods used

Stuck on a field? The guide to how to read a peptide COA walks through each part, and what a certificate of analysis is covers what a COA can and can't show.

REFScientific references

1. Pickart L, Thaler MM. Tripeptide in human serum which prolongs survival of normal liver cells and stimulates growth in neoplastic liver. Nat New Biol. 1973;243(124):85-7. PubMed 4349963
   in vitro study
2. Hureau C, Eury H, Guillot R, et al. X-ray and solution structures of Cu(II) GHK and Cu(II) DAHK complexes: influence on their redox properties. Chemistry. 2011;17(36):10151-60. PubMed 21780203
   in vitro (structural chemistry) study
3. Low TL, Hu SK, Goldstein AL. Complete amino acid sequence of bovine thymosin beta 4: a thymic hormone that induces terminal deoxynucleotidyl transferase activity in thymocyte populations. Proc Natl Acad Sci U S A. 1981;78(2):1162-6. PubMed 6940133
   in vitro (protein sequencing) study
4. Sosne G, Qiu P, Goldstein AL, Wheater M. Biological activities of thymosin beta4 defined by active sites in short peptide sequences. FASEB J. 2010;24(7):2144-51. PubMed 20179146
   review
5. Chang CH, Tsai WC, Hsu YH, Pang JH. Pentadecapeptide BPC 157 enhances the growth hormone receptor expression in tendon fibroblasts. Molecules. 2014;19(11):19066-77. PubMed 25415472
   in vitro study
6. Vasireddi N, Hahamyan H, Salata MJ, et al. Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review. HSS J. 2025;21(4):485-495. PubMed 40756949
   systematic review